<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-SPIRONOLACTONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>With the spironolactone in dosages from 12.5 to 50 mg per day, and with weak doses of the ACE inhibitor.

In the treatment of class III or IV heart failure (NYHA) with an ejection fraction &lt;35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescription conditions for this combination of medications. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict biological monitoring of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-SPIRONOLACTONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of blocking of the action of the mitotane by the spironolactone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
